| scholarly article | Q13442814 |
| P50 | author | Makoto Otsu | Q42795809 |
| Koji Eto | Q87047082 | ||
| Hiromitsu Nakauchi | Q106558120 | ||
| Shinji Hirata | Q114555975 | ||
| P2093 | author name string | Shinji Kunishima | |
| Takeaki Dohda | |||
| Naoya Takayama | |||
| Shin Kaneko | |||
| Sou Nakamura | |||
| Hiroshi Endo | |||
| Masanori Nishi | |||
| Ryoko Jono-Ohnishi | |||
| Ei-ichi Ishii | |||
| Yuhei Hamazaki | |||
| P2860 | cites work | Production of embryonic and fetal-like red blood cells from human induced pluripotent stem cells | Q21560913 |
| Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation | Q24322925 | ||
| The molecular mechanisms that control thrombopoiesis | Q24536138 | ||
| Functional cross-antagonism between transcription factors FLI-1 and EKLF | Q24541389 | ||
| Disease-specific induced pluripotent stem cells | Q24641981 | ||
| MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors | Q24653639 | ||
| Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia | Q24672498 | ||
| Pluripotent stem cells reveal the developmental biology of human megakaryocytes and provide a source of platelets for clinical application | Q27026899 | ||
| c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia | Q28141146 | ||
| The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl | Q28287528 | ||
| The WAVE2/Abi1 complex differentially regulates megakaryocyte development and spreading: implications for platelet biogenesis and spreading machinery | Q28589476 | ||
| Modeling familial Alzheimer's disease with induced pluripotent stem cells | Q42817521 | ||
| Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis | Q42972239 | ||
| Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. | Q51758016 | ||
| Critical Role of Thrombopoietin in Maintaining Adult Quiescent Hematopoietic Stem Cells | Q57362319 | ||
| Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets | Q71078405 | ||
| Low levels of erythroid and myeloid progenitors in thrombopoietin-and c-mpl-deficient mice | Q71249503 | ||
| Recombinant human thrombopoietin (Mpl ligand) enhances proliferation of erythroid progenitors | Q71709650 | ||
| Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts | Q79795007 | ||
| Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors | Q81015137 | ||
| In vitro generation of megakaryocytes and platelets from human embryonic stem cells and induced pluripotent stem cells | Q82750313 | ||
| Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells | Q29615870 | ||
| Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons | Q29616199 | ||
| Metalloproteinase regulation improves in vitro generation of efficacious platelets from mouse embryonic stem cells | Q30483213 | ||
| Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. | Q30489278 | ||
| Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. | Q30539904 | ||
| Successful bone marrow transplantation in a patient with c-mpl-mutated congenital amegakaryocytic thrombocytopenia from a carrier donor | Q33364656 | ||
| The biogenesis of platelets from megakaryocyte proplatelets | Q33369405 | ||
| Congenital amegakaryocytic thrombocytopenia: a retrospective clinical analysis of 20 patients | Q33369564 | ||
| JAK and MPL mutations in myeloid malignancies | Q33378737 | ||
| Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells | Q33392928 | ||
| Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets | Q33495175 | ||
| Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl | Q33495712 | ||
| Defective response to thrombopoietin and impaired expression of c-mpl mRNA of bone marrow cells in congenital amegakaryocytic thrombocytopenia | Q33498429 | ||
| Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders | Q33560423 | ||
| Biologic properties and enucleation of red blood cells from human embryonic stem cells | Q34013422 | ||
| In vivo generation of transplantable human hematopoietic cells from induced pluripotent stem cells. | Q34034653 | ||
| Generation of engraftable hematopoietic stem cells from induced pluripotent stem cells by way of teratoma formation. | Q34036700 | ||
| Human induced pluripotent stem cells can reach complete terminal maturation: in vivo and in vitro evidence in the erythropoietic differentiation model. | Q34284032 | ||
| MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia | Q34770384 | ||
| Transcription factor networks in erythroid cell and megakaryocyte development | Q35112203 | ||
| Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease | Q35525329 | ||
| Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics | Q35571380 | ||
| Leukosialin (CD43) defines hematopoietic progenitors in human embryonic stem cell differentiation cultures | Q35849083 | ||
| Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability | Q35889309 | ||
| Eltrombopag and improved hematopoiesis in refractory aplastic anemia | Q36174878 | ||
| Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin | Q36366315 | ||
| YRRL motifs in the cytoplasmic domain of the thrombopoietin receptor regulate receptor internalization and degradation | Q36868698 | ||
| The multiple lives of NMD factors: balancing roles in gene and genome regulation | Q37013877 | ||
| A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes | Q37251604 | ||
| Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells | Q37287210 | ||
| Novel pathways to erythropoiesis induced by dimerization of intracellular C-Mpl in human hematopoietic progenitors | Q37680060 | ||
| A common bipotent progenitor generates the erythroid and megakaryocyte lineages in embryonic stem cell-derived primitive hematopoiesis. | Q39845785 | ||
| EKLF restricts megakaryocytic differentiation at the benefit of erythrocytic differentiation | Q39975723 | ||
| Downregulation of signal transducer and activator of transcription 5 (STAT5) in CD34+ cells promotes megakaryocytic development, whereas activation of STAT5 drives erythropoiesis | Q39988310 | ||
| Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. | Q39997716 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | thrombocytopenia | Q585285 |
| congenital disorder | Q727096 | ||
| congenital amegakaryocytic thrombocytopenia | Q5160405 | ||
| P304 | page(s) | 3802-3814 | |
| P577 | publication date | 2013-08-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Congenital amegakaryocytic thrombocytopenia iPS cells exhibit defective MPL-mediated signaling | |
| P478 | volume | 123 |
| Q33442532 | Bleeding is not the main clinical issue in many patients with inherited thrombocytopaenias |
| Q37633372 | Concise Review: Getting to the Core of Inherited Bone Marrow Failures. |
| Q89804990 | Diagnosis of Inherited Platelet Disorders on a Blood Smear |
| Q26866409 | Disease modeling and cell based therapy with iPSC: future therapeutic option with fast and safe application |
| Q33425856 | Durable engraftment and correction of hematological abnormalities in children with congenital amegakaryocytic thrombocytopenia following myeloablative umbilical cord blood transplantation |
| Q27308743 | Early pathogenesis of Duchenne muscular dystrophy modelled in patient-derived human induced pluripotent stem cells. |
| Q33436518 | Establishment of a congenital amegakaryocytic thrombocytopenia model and a thrombocyte-specific reporter line in zebrafish. |
| Q33413336 | Expandable megakaryocyte cell lines enable clinically applicable generation of platelets from human induced pluripotent stem cells |
| Q27318499 | Functional comparison of induced pluripotent stem cell- and blood-derived GPIIbIIIa deficient platelets |
| Q36829190 | Genome Editing of the CYP1A1 Locus in iPSCs as a Platform to Map AHR Expression throughout Human Development |
| Q49989075 | Hereditary thrombocytopenias: a growing list of disorders |
| Q64069475 | Human induced pluripotent stem cell models for the study and treatment of Duchenne and Becker muscular dystrophies |
| Q34394559 | Immortalization of erythroblasts by c-MYC and BCL-XL enables large-scale erythrocyte production from human pluripotent stem cells |
| Q33914515 | Induced Pluripotent Stem Cells: Global Research Trends |
| Q33432109 | Inherited thrombocytopenias-recent advances in clinical and molecular aspects |
| Q59384150 | Insights in Megakaryopoiesis and Platelet Biogenesis from Studies of Inherited Thrombocytopenias |
| Q33413048 | Lessons in platelet production from inherited thrombocytopenias |
| Q26770863 | Linkage between the mechanisms of thrombocytopenia and thrombopoiesis |
| Q28083303 | Modeling Human Bone Marrow Failure Syndromes Using Pluripotent Stem Cells and Genome Engineering |
| Q92570903 | Modeling blood diseases with human induced pluripotent stem cells |
| Q41386729 | Multicolor staining of globin subtypes reveals impaired globin switching during erythropoiesis in human pluripotent stem cells |
| Q41849202 | Murine iPSC-Derived Macrophages as a Tool for Disease Modeling of Hereditary Pulmonary Alveolar Proteinosis due to Csf2rb Deficiency |
| Q61797733 | Platelets inhibit apoptotic lung epithelial cell death and protect mice against infection-induced lung injury |
| Q39076420 | Progress in bio-manufacture of platelets for transfusion |
| Q42247805 | Selective Inhibition of ADAM17 Efficiently Mediates Glycoprotein Ibα Retention During Ex Vivo Generation of Human Induced Pluripotent Stem Cell-Derived Platelets |
| Q26862370 | Stem cells, megakaryocytes, and platelets |
| Q39063423 | Ten years of iPSC: clinical potential and advances in vitro hematopoietic differentiation |
| Q48207367 | Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim |
| Q60310904 | Transcription Factor Levels after Forward Programming of Human Pluripotent Stem Cells with GATA1, FLI1, and TAL1 Determine Megakaryocyte versus Erythroid Cell Fate Decision |
| Q42285520 | Transdifferentiation of Human Hair Follicle Mesenchymal Stem Cells into Red Blood Cells by OCT4. |
| Q58784425 | Tyrosyl-tRNA synthetase stimulates thrombopoietin-independent hematopoiesis accelerating recovery from thrombocytopenia |
| Q26751506 | hiPSC-derived iMSCs: NextGen MSCs as an advanced therapeutically active cell resource for regenerative medicine |
Search more.